Eli Lilly (LLY) will collaborate with privately held biotech InduPro to use the latter’s proximity-guided platform to develop new oncology treatments.
InduPro’s platform, known as Mint, “leverages deep learning analysis of proprietary protein microenvironment and membrane proteomic data to define the architecture of the cell surface proteome across different target classes and indications,” that company says. As a result, it can “identify novel targets and co-target pairs for selective tumor targeting (bispecific [antibody-drug conjugates and t-cell engagers]) or immunological synapse modulation (bi/multispecific mAbs).”
Terms call for Lilly and InduPro to work on up to three targets, for a deal value of up to $950M. Lilly will also make an equity investment in InduPro.
InduPro will take charge of early discovery efforts “to identify co-target pairs and advance bispecific and multispecific antibody programs emerging from the collaboration,” according to a news release.
